Jennison Associates

Jennison Associates

Jennison Associates

Active fundamental manager with single focus, strong investment culture and superior investment returns across capabilities for 45 years
Follow us
the home of AI info

Unum Therapeutics Inc. (UMRX)'s Financial Results Comparing With Minerva Neurosciences Inc ...


With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite

MedCity News

Editas Medicine CEO steps down as company moves into product development stage

$69,200,000 IPO

VC-backed Unum Therapeutics rolls out IPO

Stock markets Health

Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies

Health Stock markets
$75,000,000 IPO

With $75M Haul, Ovid Continues Flurry of Biotech IPOs

Health Science
$15,000,000 Debt financing

Unum Therapeutics Receives $15M Credit Facility from Square 1 Bank


Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M

Health Strategy Earnings

Still Stuck Below IPO Price, Merrimack Restructures, CEO Resigns

Health Earnings
The Motley Fool

Here's Why Merrimack Pharmaceuticals' Stock Has Been Getting Crushed in 2016

The Motley Fool

Why Merrimack Pharmaceuticals' Stock Is Sliding Today

$94,000,000 IPO
GeekWire , WIRED

Editas Medicine raises $94M in first gene-editing IPO, and then stock price rises

Science Stock markets

As Markets and Controversies Swirl, Editas Aims For $100M CRISPR IPO

Science Health
The Motley Fool

Natera, Inc. Surged 20% Higher in December. Here's Why. --

Stock markets

Gates-backed Editas Medicine files for IPO, marking CRISPR gene-editing milestone

Science Funding
$75,000,000 Venture capital (Series B)

Ex-Teva CEO's Brain Disease Startup, Ovid, Bags $75M From Crossovers

Health Funding

Prenatal Tester Natera Now Shooting for $175M IPO

Health Funding